{Reference Type}: Journal Article
{Title}: Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France.
{Author}: Saint F;Pasquier D;Villers A;Massa J;Colin P;Vankemmel O;Leroy X;Bonnal JL;Plouvier SD;
{Journal}: Fr J Urol
{Volume}: 34
{Issue}: 9
{Year}: 2024 Jul 3
暂无{DOI}: 10.1016/j.fjurol.2024.102675
{Abstract}: <B>OBJECTIVE: </B>Information on bladder cancer (BC) according to the risk scoring for recurrence or progression in a general population is scarce despite its clinical relevance. The objective was to describe the characteristics of incident BC in a general population, with a focus on the initial management of high-risk non-muscle invasive BC (HR-NMIBC).<BR><B>METHODS: </B>BC incident in 2011-2012 recorded in a population-based cancer registry were studied. Data was extracted from medical files. NMIBC were classified according to potential risk for recurrence/progression. Individual and tumor characteristics of incident BC were described. Incidence, initial management and survival (12/31/2021) of HR-NMIBC were assessed.<BR><B>RESULTS: </B>Among 538 BC cases, 380 were NMIBC [119 low (22.1%), 163 intermediate (30.3%), 98 high (18.2%) risk] and 147 (27.3%) were MIBC. HR-NMIBC diagnostic and therapeutic management [imaging, re-TUR, multidisciplinary team meetings (MDT) assessment, specific treatment] revealed discrepancies with guidelines recommendations. Seventy-two out of 98 cases were assessed in an MDT with a median time from diagnosis of 18days [first quartile: 12-third quartile: 32]. Globally, treatment agreed with MDT decisions. Intravesical instillation was the most common treatment (n=56) but 27 HR-NMIBC did not receive specific treatment after TUR. Five and 10years overall survival was 52% [42-63] and 41% [31-51], respectively. Five years net survival was 63% [47-75].<BR><B>CONCLUSIONS: </B>Despite National cancer plans aiming to improve care giving and despite the severity of HR-NMIBC, guideline-recommended patterns of care were underused in this region. This may deserve attention to identify obstacles to guideline adoption to try to improve BC patient care and survival.<BR><B>METHODS: </B>